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Abstract
Background: Abnormalities in cerebrospinal fluid (CSF) production and turnover, seen in normal
pressure hydrocephalus (NPH) and in Alzheimer's disease (AD), may be an important cause of
amyloid retention in the brain and may relate the two diseases. There is a high incidence of AD
pathology in patients being shunted for NPH, the AD-NPH syndrome. We now report elevated
CSF pressure (CSFP), consistent with very early hydrocephalus, in a subset of AD patients enrolled
in a clinical trial of chronic low-flow CSF drainage. Our objective was to determine the frequency
of elevated CSFP in subjects meeting National Institutes of Neurological and Communicative
Diseases and Stroke – Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
criteria for AD, excluding those with signs of concomitant NPH.
Methods:  AD subjects by NINCDS-ADRDA criteria (n = 222), were screened by history,
neurological examination, and radiographic imaging to exclude those with clinical or radiographic
signs of NPH. As part of this exclusion process, opening CSFP was measured supine under general
anesthesia during device implantation surgery at a controlled pCO2 of 40 Torr (40 mmHg).
Results: Of the 222 AD subjects 181 had pressure measurements recorded. Seven subjects (3.9%)
enrolled in the study had CSFP of 220 mmH20 or greater, mean 249 ± 20 mmH20 which was
significantly higher than 103 ± 47 mmH2O for the AD-only group. AD-NPH patients were
significantly younger and significantly less demented on the Mattis Dementia Rating Scale (MDRS).
Conclusion: Of the AD subjects who were carefully screened to exclude those with clinical NPH,
4% had elevated CSFP. These subjects were presumed to have the AD-NPH syndrome and were
withdrawn from the remainder of the study.
Background
Alzheimer's disease (AD) and adult-onset, idiopathic
chronic hydrocephalus, or normal pressure hydrocepha-
lus (NPH), are age-related disorders involving various
degrees of dementia. Patients with both diseases have
reduced cerebrospinal fluid (CSF) production and
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decreased CSF turnover that may be associated with a
decreased ability to clear potentially toxic metabolites,
such as amyloid beta-peptides (Aβ) [1]. Several clinical
series have documented the surprisingly high frequency of
pathologically confirmed AD in patients meeting clinical
criteria for NPH. In one series, seven of 21 NPH patients
(33%) who underwent cortical biopsy at the time of ven-
triculo-peritoneal shunt implantation, had neuropatho-
logical changes consistent with AD [2]. In two other series,
one-quarter to one-half of NPH patients had AD-type neu-
ropathology [3,4]. In a more recent series, 23 of 55
patients (42%) biopsied at the time of shunt placement
for NPH met CERAD (Consortium to establish a registry
for Alzheimer's disease) criteria for AD [5], including 75%
of those with severe dementia [6]. There have been no cor-
ollary studies addressing the occurrence of raised CSFP
among patients with clinical AD, who have not yet devel-
oped the clinical syndrome or radiographic features of
NPH.
The therapeutic objective guiding low-flow ventricu-
loperitoneal shunting as a treatment for AD was to
improve safely the CSF turnover and clearance of meta-
bolic by-products, such as Aβ and tau, from the brain [7].
A clinical trial designed to evaluate the safety and efficacy
of low-flow shunting in subjects that met strict National
Institutes of Neurological and Communicative Diseases
and Stroke – Alzheimer's Disease and Related Disorders
Association (NINCDS-ADRDA) criteria for probable AD
[8] required that opening CSF pressure (CSFP) be meas-
ured under controlled blood pressure, oxygenation and
pCO2 prior to shunt implantation. This allowed an esti-
mate of the frequency of elevated CSFP and, therefore,
presumed early NPH, in patients with AD, and a compar-
ison between AD sub-groups with and without coexistent
elevated CSFP. The data from the clinical trial will be the
subject of a separate communication.
Methods
The subjects in this trial were enrolled at 25 medical cent-
ers in the USA in an FDA (Federal Drug Administration)
approved clinical trial of low-flow CSF shunting for AD,
FDA IDE (investigational device exemption) # G 970117,
protocol # 2000–01. AD subjects enrolled in the trial were
in the mild to moderate phase of the disease, as indicated
by a mini-mental status exam (MMSE) between 15 and
26. All subjects and their caregivers signed an informed
consent as part of the experimental protocol approved by
the Institutional Review Board at each center.
The 222 subjects who completed all screening and base-
line assessments were randomized to receive either a func-
tioning shunt or one that was intentionally occluded.
During clinical screening and baseline psychometric test-
ing prior to implantation of the shunt, subjects meeting
strict NINCDS-ADRDA were carefully evaluated to
exclude those with clinical, radiographic, or CSFP signs of
NPH. By protocol these included:
1. Gait apraxia or gait ataxia, particularly one that pre-
ceded the onset of dementia. Gait apraxia (magnetic gait)
was defined as the inability to initiate the lower extremity
movements necessary for ambulation, not explained by
leg weakness or an orthopedic condition.
2. Urinary incontinence not due to a focal, defined genito-
urinary abnormality.
3. Imaging studies indicating significant enlargement of
the ventricles out of proportion to the amount of cerebral
atrophy. All imaging studies were independently evalu-
ated for evidence of NPH by a neuroradiologist. Subjects
with enlarged ventricles had an assessment of the degree
of atrophy of the hippocampus by measuring the degree
of dilation of the perihippocampal fissures (PHF), the fis-
sures that surround the hippocampus. These include the
lateral aspect of the transverse fissure, the choroidal fis-
sure and the hippocampal fissure. Subjects with enlarged
ventricles and normal or mildly dilated PHF (as seen in
NPH) were excluded, whereas those with moderately or
markedly dilated PHF (significant hippocampal atrophy
as seen in AD) were eligible for enrollment [9].
Those subjects meeting all screening and baseline entry
criteria were eligible for investigational device implanta-
tion, at which time a final entry criterion of CSFP was eval-
uated:
4. CSFP greater than 200 mmH2O was measured during
initial shunt implantation surgery under general anesthe-
sia in the standard supine position via the implanted ven-
tricular catheter. Blood pressure and oxygenation were
stable within normal parameters. The pCO2 was control-
led at 40 Torr (end tidal CO2 36–37 Torr) prior to ven-
tricular cannulation. Anesthesia consisted of propofol
infusion supplemented with low dose isoflurane (<0.5%)
and/or nitrous oxide (50%). As previously described,
these agents do not alter CSFP [10]. Under these control-
led conditions CSFP stabilized within 5–10 minutes. The
opening pressure was monitored by a manometer
attached to the ventricular catheter, and recorded after the
CSFP had stabilized. The manometer stopcock was posi-
tioned at approximately the mid-ventricular level. If the
opening CSFP was >200 mmH2O, generally accepted as
the upper limit of normal CSFP in adults, the subject was
excluded from the trial by protocol, because of probable
associated early NPH. Such subjects were treated with the
standard of care for NPH at the enrolling center, and at the
discretion of the neurosurgeon, a conventional hydro-
cephalus shunt could be implantedCerebrospinal Fluid Research 2006, 3:7 http://www.cerebrospinalfluidresearch.com/content/3/1/7
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The subjects with elevated CSFP (AD-elevated CSFP
group) were compared to the AD subjects whose CSFP
was 200 mmH2O or less (AD-only group). Differences
between the two groups in CSFP, age and in baseline Mat-
tis Dementia Rating Scale (MDRS) scores were assessed by
Student's t test (St) and confirmed by the non-parametric
Mann-Whitney two independent groups comparison
(MW). The MDRS was one of the primary end-points of
the study and is a comprehensive multipart test of cogni-
tive function [11].
Results
Of the 222 AD subjects with no clinical or radiological
evidence of NPH who underwent general anesthesia for
implantation of an investigational device, 181 subjects
had CSFP data that could be evaluated. The remainder
either did not have opening CSFP recorded for a variety of
reasons, e.g. CSF was removed or lost prior to the pressure
measurement, the CSFP was never recorded or the data
were not available at the time of this analysis. These
appeared to be random events and should not have intro-
duced bias into the data. During the initial implantation
procedure, seven of the 181 subjects (3.9%) with no clin-
ical or radiographic signs of NPH had an opening CSFP
>200 mmH2O (the AD-elevated CSFP group). These sub-
jects were withdrawn from the CSF drainage trial. There-
fore, they did not have an investigational device
implanted nor was their follow up clinical assessment
available in the case files.
The AD-only group comprised 174 subjects whose open-
ing CSFP at implantation surgery was 200 mmH2O or less.
The mean age of this group was 74 ± 6 years. The mean
MDRS score was 106 ± 17. Mean opening CSFP in the AD-
only group was 103 ± 47 mmH2O. For the AD-elevated
CSFP group, the mean CSFP was 249 ± 20 mmH2O (range
220–280 mmH2O), which was significantly elevated
when compared to the AD-only group, St P = 0.001, MW
P < 0.0001 (Figure 1). The distribution of CSFP in the two
populations is shown in Figure 2. The mean age of this
subset of AD patients with elevated CSFP was significantly
younger, 67 ± 6 years vs. 74 ± 6, (StP = 0.015, MW P <
0.005) and the MDRS scores were significantly higher,
118 ± 6 (range 127–109) vs. 106 ± 17 (range 137–54),
than the AD-only subjects, StP = 0.001, MW P < 0.04).
Baseline characteristics of these subjects, who we consid-
ered examples of the AD-NPH syndrome, are provided in
Table 1.
Discussion
Aging affects the CSF circulation in a number of ways [12],
at least two of which influence CSF circulatory dynamics.
First, there is a trend toward decreased CSF production,
with a concomitant decrease in CSF turnover [13]. Sec-
ond, there is an increased resistance to CSF outflow result-
ing in decreased CSF absorption [14]. Age-related
accumulations of amyloid in the choroid plexus and
meninges, fibrosis, thickening of the basement mem-
brane, and senescent changes in the choroidal epithelium
and choroidal vasculature probably play a role both in
decreased CSF production and decreased CSF absorption
in normal aging, in NPH and in AD [1,12,15,16]. Reduced
CSF production and turnover have been demonstrated in
both AD and NPH patients [1,10,17].
Frequency histogram showing the distribution of CSFP in all  subjects Figure 2
Frequency histogram showing the distribution of CSFP in all 
subjects. Note the two separate pressure peaks, the larger 
peak corresponding to the AD-only group, and a smaller 
peak corresponding to the AD-NPH group.
Histogram CSFP Across Population
0
5
10
15
20
25
30
35
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280
CSFP (mm H2O)
p
o
p
u
l
a
t
i
o
n
 
(
s
u
b
j
e
c
t
s
)
AD
Presumed NPH
Bar graph of the mean opening pressure (CSFP) in the AD- NPH subjects, mean 249 ± 20 mmH2O, compared with the  AD only subjects, mean 103 ± 47 mmH2O, StP = 0 Figure 1
Bar graph of the mean opening pressure (CSFP) in the AD-
NPH subjects, mean 249 ± 20 mmH2O, compared with the 
AD only subjects, mean 103 ± 47 mmH2O, StP = 0.001, MW 
P < 0.0001.
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Growth factors that induce fibrosis may play a role in
developing increased resistance to CSF absorption in
some patients with AD. There appears to be an increase in
the CSF concentration of transforming growth factor beta-
1 (TGFβ-1) as well as an increase in brain fibroblast
growth factor-2 (FGF-2) in patients with AD [18-20]. It
has been shown in a transgenic mouse model, in which
astrocytes over-express TGFβ-1, that hydrocephalus
ensues [21]. In a rat model of FGF-2-induced hydroceph-
alus, both decreased CSF production and increased fibro-
sis of the CSF absorption pathways were demonstrated
[20]. The hydrocephalus appears to be due to an increased
fibrosis of the arachnoidal villi in these animal models.
The AD subjects with increased CSFP in this report can-
not, strictly speaking, be called NPH, since they had nei-
ther the clinical syndrome nor the enlarged ventricles
associated with NPH, otherwise they would have been
excluded from enrollment. NPH itself is something of a
misnomer, since patients tend to have high-normal CSF
pressures with intervals of frankly elevated pressures, par-
ticularly during REM sleep [22]. Although NPH was so-
named because CSFP is within the physiological range
when sampled by lumbar puncture during the day [23],
many studies (infusion tests and chronic CSFP monitor-
ing) in human subjects and animals have shown that CSF
dynamics in this syndrome are significantly altered [24-
27]. There is increased resistance to CSF absorption and
decreased compliance within the CNS. CSF abnormalities
are manifest not only by abnormalities in CSF infusion
tests [28], but also by nocturnal elevations in CSFP
accompanied by plateau waves [24].
In an animal model of NPH, kaolin-induced hydrocepha-
lus, CSFP is initially elevated but soon returns to the phys-
iological range after ventricular dilatation, decreased CSF
production and other compensatory events occur [29].
The individuals described herein demonstrated elevated
CSFP well outside the usual CSFP associated with AD (103
± 47 mmH2O) or typically found in non-demented, simi-
larly aged controls (140 ± 60 mmH2O) [17]. It would be
reasonable to anticipate that the patients in this study
with elevated CSFP were in the earliest stages of this proc-
ess at the time that their elevated pressures were discov-
ered, and that over time they would go on to develop
enlarged ventricles and clinical signs of NPH. It is also of
interest that in the aged rat model of kaolin hydrocepha-
lus, Aβ (1–40) and Aβ (1–42) accumulate in the brain
compared to age-matched controls [30].
The prevalence of NPH is estimated to be one per 100,000
and that of AD is about 10% of the population over age
65 [1]. The coincidence of AD neuropathology among
patients with NPH varies from 25–75% depending upon
the severity of the clinical dementia. This is greater than
one would anticipate if the two diseases were unrelated.
Based on the current series, the approximately 4% coinci-
dence of elevated CSFP, and presumed early hydrocepha-
Table 1: Baseline characteristics of the seven AD-NPH subjects. The imaging studies were read by an independent neuroradiologist. 
The normal MDRS score is 142–144, the normal MMSE score is 27–30. Consequently, these patients are in the mild to moderate range 
of AD.
Subject number 12 3 4 5 6 7
Age 68 66 63 71 73 56 70
Gender Male Female Female Male Male Female Male
Highest Education <8th Grade 8th – 12th Grade >12th Grade >12th Grade 8th -12th Grade 8th – 12th Grade 8th – 12th Grade
Neurological History 
(other than AD)
None None None None None Restless legs Insomnia, headaches
Genitourinary History Urinary 
Tract 
Infection, 
prostatitis
None None None None None Overactive bladder, 
prostate hypertrophy
Abnormal Posture Absent Absent Absent Absent Absent Absent Absent
Brain Image Type MRI MRI MRI CT MRI MRI CT
Markedly Enlarged 
Ventricles?
No No No No No No No
Other Lesions on 
Brain Scan
None Non-specific 
deep white 
matter changes
Small amt 
periventricular 
white matter 
changes
None Mild changes 
noted on Flair 
image
None None
Gait Normal Normal Normal Normal Normal Normal Poor balance, unable 
to tandem gait, slow 
gait, no arm swinging
MDRS 111 123 127 120 120 118 109
MMSE 19 25 26 25 21 20 26
Opening pressure 240 235 260 260 250 220 280Cerebrospinal Fluid Research 2006, 3:7 http://www.cerebrospinalfluidresearch.com/content/3/1/7
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lus, among carefully selected AD patients is also greater
than one would anticipate if the two diseases were unre-
lated.
It has been suggested that both AD and NPH are physio-
logically related to CSF circulatory failure [1]. If CSF fail-
ure (diminished CSF production and impaired choroid
plexus transport) predominates, then AD may manifest
initially. If decreased absorption, on the other hand, is the
predominate manifestation of CSF circulatory failure,
then NPH may emerge first. Once either disease process
begins, the risk for the other disease may increase. For
example, in the setting of pre-existing AD, NPH could
arise with an increase in CSF outflow resistance due to
amyloid deposition and fibrosis in the meninges and
arachnoid granulations. Relative CSFP elevations result-
ing from increasing outflow resistance might lead to man-
ifestations of NPH superimposed on AD. Similarly,
among individuals with NPH at onset, amyloid clearance
could be compromised by pathologic changes in outflow
resistance, leading to cerebral amyloidosis and increased
risk of AD. In either scenario, the two diseases could ulti-
mately converge, resulting in an AD-NPH "hybrid".
Conclusion
As observed in previous series, an important subgroup of
patients with NPH also meets pathological criteria for AD
and exhibit features of both diseases. This series represents
the first set of observations documenting evidence of
raised CSFP, suggesting early NPH, among carefully
selected AD subjects. Despite strict clinical criteria
intended to exclude NPH, elevated CSFP was observed in
3.9% of our enrolled AD study subjects. As noted, due to
our strict exclusion criteria, this is likely to be a marked
underestimation of the true incidence of this nosologic
"hybrid", (closer to the approximately 50% incidence
recorded in the NPH patients studies to date). The exist-
ence of such an AD-NPH hybrid suggests that these two
diseases represent two ends of the spectrum of CSF circu-
latory failure.
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